Breaking Finance News

Janney Montgomery Scott upgraded Galapagos NV (ADR) (NASDAQ:GLPG) to Neutral in a report released today.

Janney Montgomery Scott has upgraded Galapagos NV (ADR) (NASDAQ:GLPG) to Neutral in a report released on 07/07/2017.

Previously on Tuesday June 20, 2017, BTIG Research reported about Galapagos NV (ADR) (NASDAQ:GLPG) raised the target price from $0.00 to $98.00. At the time, this indicated a possible upside of 0.23%.

Yesterday Galapagos NV (ADR) (NASDAQ:GLPG) traded 3.29% higher at $75.63. The company’s 50-day moving average is $0.00 and its 200-day moving average is $0.00. The last stock close price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 353,470 shares of the stock were exchanged, up from an average trading volume of 0

See Chart Below

Galapagos NV (ADR) (NASDAQ:GLPG)

Galapagos NV (ADR) has a 52 week low of $52.50 and a 52 week high of $94.88 The company’s market cap is currently $0.

In addition to Janney Montgomery Scott reporting its target price, a total of 1 firm has reported on the stock. The consensus target price is $92.78 with 0 firms rating the stock a strong buy, 2 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Galapagos NV (ADR) (NASDAQ:GLPG)

Galapagos NV is a Belgium-based biotechnology company. The Company's activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. As of December 31, 2011, Galapagos NV was, through its subsidiaries, active in Belgium, France, Switzerland, the Netherlands, the United Kingdom, Germany, the United States and Croatia. In April 2014, it sold BioFocus and Argenta service division operations to Charles River Laboratories International.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.